Amgen (AMGN) Equity Income (2020 - 2025)

Amgen has reported Equity Income for 6 years, with the latest figure at $10.0 million in Q3 2025.

• On a quarterly basis, Equity Income rose 135.71% year-over-year to $10.0 million in Q3 2025; TTM through Sep 2025 was -$20.0 million, a 17.65% decrease from a year earlier, with the FY2024 full-year figure at $10.0 million, up 190.91% from the prior year.
• Equity Income was $10.0 million for Q3 2025 at Amgen, up from -$18.0 million in the prior quarter.
• The five-year high for Equity Income was $97.0 million in Q4 2021, with the low at -$305.0 million in Q1 2022.
• Average Equity Income over 5 years is -$31.0 million, with a median of -$11.0 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2024: Equity Income plunged 671.43% in 2022, then surged 142.86% in 2024.
• Over 5 years, Equity Income stood at $97.0 million in 2021, then slumped by 283.51% to -$178.0 million in 2022, then soared by 84.27% to -$28.0 million in 2023, then jumped by 96.43% to -$1.0 million in 2024, then surged by 1100.0% to $10.0 million in 2025.
• The last three Equity Income figures came in at $10.0 million (Q3 2025), -$18.0 million (Q2 2025), and -$11.0 million (Q1 2025), per Business Quant data.